$ABP - As of July 2025, Abpro Corp. (NASDAQ: ABP)
Post# of 29764
Abpro is a biotech company developing next-generation antibody therapies for:
Cancer (immuno-oncology)
Ophthalmology (eye diseases)
They use two proprietary platforms:
DiversImmune™ – Generates a wide range of antibodies against both known and novel disease targets.
MultiMab™ – Allows flexible engineering of multi-specific antibodies, combining different antibody fragments into one therapy.

